Delving into the Latest Updates on Tamsulosin Hydrochloride with Synapse

Overview

Basic Info

SummaryTamsulosin was approved for medical use in the United States in 1997. Specifically it is an α1 adrenergic receptor blocker. Tamsulosin, sold under the brand name Flomax among others, is a medication used to treat symptomatic benign prostatic hyperplasia (BPH) and chronic prostatitis and to help with the passage of kidney stones. The evidence for benefit with a kidney stone is better when the stone is larger. It is taken by mouth. Common side effects include dizziness, headache, sleeplessness, nausea, blurry vision, and sexual problems. Other side effects may include feeling lightheaded with standing and angioedema. Tamsulosin is an alpha blocker and works by relaxing muscles in the prostate.

Drug Type

Small molecule drug

Synonyms

(-)-tamsulosin, (R)-(-)-tamsulosin, (R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide

+ [36]

Target

α1A-AR

Action

antagonists

Mechanism

α1A-AR antagonists(Alpha-1a adrenergic receptor antagonists)

Therapeutic Areas

Urogenital DiseasesOther Diseases

Active Indication

Lower Urinary Tract SymptomsProstatic Hyperplasia

Inactive Indication

Acute retention of urineDysuriaErectile Dysfunction+ [5]

Originator Organization

Astellas Pharma, Inc.

Active Organization

Astellas Pharma Europe BV

Astellas Pharma, Inc.Astellas Pharma Australia Pty Ltd.

+ [2]

Inactive Organization

Boehringer Ingelheim GmbH

Astellas Pharma China, Inc.Astellas Pharma Europe Ltd.

+ [1]

License Organization

Qingdao Baheal Medical, Inc.

Astellas Pharma, Inc.

Drug Highest PhaseApproved

First Approval Date

Japan (02 Jul 1993),

Prostatic Hyperplasia

RegulationPriority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC20H29ClN2O5S

InChIKeyZZIZZTHXZRDOFM-XFULWGLBSA-N

CAS Registry106463-17-6

View All Structures (2)

Holmium Laser Enucleation of the Prostate (HoLEP) is an increasingly popular endoscopic minimally invasive surgical technique for the treatment of benign prostatic hyperplasia (BPH). In the literature, the long-term efficacy and low complication rates of HoLEP have been highlighted in many studies. However, in the early postoperative period, particularly within the first three months, irritative symptoms are reported in 17-35% of cases (1-2).
The pathophysiology of postoperative irritative symptoms is not yet fully understood, but it has been suggested that these symptoms may be associated with urethral trauma, the mucosal healing process, and detrusor overactivity. These symptoms can significantly impact quality of life, reducing patient satisfaction. In particular, dysuria is a frequently encountered symptom after HoLEP, with considerable individual variability in its severity and duration.
The effectiveness of alpha-blockers in alleviating postoperative dysuria and irritative symptoms remains a topic of debate in the literature. Although prostate tissue is surgically removed, alpha-blockers may improve urinary flow and relieve symptoms associated with bladder outlet obstruction by reducing urethral smooth muscle tone (3). Studies on the use of alpha-blockers following transurethral resection of the prostate (TURP) have shown limited postoperative benefits (4). However, to the best of our knowledge, no study has specifically evaluated their use following HoLEP, an enucleation-based technique. Therefore, further studies are needed to assess the role of alpha-blockers in managing dysuria after HoLEP.
The aim of this study is to evaluate the effectiveness of alpha-blocker therapy in managing dysuria and other irritative symptoms following HoLEP. Additionally, the study seeks to determine the impact of this treatment on quality of life and patient satisfaction.

Start Date04 Mar 2025

Sponsor / Collaborator-

NCT06843538

/ RecruitingPhase 3

Peri-operative Tamsulosin and Impact on Voiding Trial Following Outpatient Urogynecology Surgery: a Randomized Controlled Trial

The purpose of this research study is to determine if taking tamsulosin preoperatively decreases your chances of being discharged after surgery with a Foley catheter (flexible tube that drains urine from the bladder into a collection bag).

Start Date03 Feb 2025

Sponsor / Collaborator

TriHealth, Inc.

100 Clinical Results associated with Tamsulosin Hydrochloride

Login to view more data

100 Translational Medicine associated with Tamsulosin Hydrochloride

Login to view more data

100 Patents (Medical) associated with Tamsulosin Hydrochloride

Login to view more data

3,207

Literatures (Medical) associated with Tamsulosin Hydrochloride

01 Jul 2025·American Journal of Ophthalmology

Drugs Associated With Floppy Iris Syndrome: A Real-World Population-Based Study

Article

Author: Muni, Rajeev H ; Lakhani, Moiz ; Kwan, Angela T H ; Hurley, Bernard ; Popovic, Marko M ; Mihalache, Andrew

PURPOSEIntraoperative floppy iris syndrome (IFIS) is associated with an increased rate of severe intraoperative complications and greater visual morbidity during cataract surgery, particularly in females. To date, no postmarketing pharmacovigilance study has comprehensively examined all FDA-approved drugs for their association with IFIS development or explored potential sex differences. Understanding the risk factors for IFIS allows cataract surgeons to better stratify surgical risks and implement appropriate preoperative and intraoperative measures to ensure adequate management in high-risk patients.DESIGNRetrospective pharmacovigilance clinical cohort study.METHODSThis population-based, observational study analyzed IFIS cases reported to the Food and Drug Administration Adverse Event Reporting System from October 2003 to March 2024 using OpenVigil 2.1. Disproportionality metrics, including reporting odds ratios (RORs), proportional reporting ratios (PRRs), and relative risk reductions, were used to assess signals for positive adverse reactions (n > 2, χ² > 4, PRR > 2), compared to all other drugs. Subgroup analyses were also conducted by sex.RESULTSOf 12,345,128 adverse event reports, 649 (0.0053%) involved IFIS. The majority of cases were reported by healthcare professionals (75.75%, n = 203), followed by consumers (12.69%, n = 34) and unknown sources (11.57%, n = 31). Drugs with the highest disproportionality for IFIS included imipramine (ROR = 251.66, 95% confidence interval [CI] = 157.53-402.02), tamsulosin (ROR = 171.44, 95% CI = 143.12-205.36), and chlorpromazine (ROR = 91.30, 95% CI = 49.91-167.03) (all P < .0001, IC₀₂₅ > 0). Over-reported drug classes included α1-blockers, tricyclic antidepressants, atypical antipsychotics, carbonic anhydrase inhibitors, corticosteroids, 5α-reductase inhibitors, β-blockers, prostaglandin analogs, and β2-agonists. Among females, brinzolamide (ROR = 409.63, 95% CI = 196.78-852.73) and salbutamol (ROR = 67.12, 95% CI = 28.37-158.80) were disproportionately associated with IFIS (both P < .0001, IC₀₂₅ > 0), whereas these associations were not observed in males.CONCLUSIONSThis analysis of over 20,000 drugs and 12 million reports highlights that, in addition to α1-blockers and atypical antipsychotics, tricyclic antidepressants are among the key agents most disproportionately associated with IFIS, with notable sex differences. These findings are crucial for informing perioperative counseling and surgical planning for cataract surgery.

01 Jun 2025·Journal of Molecular Liquids

Volumetric and sonometric properties of ionic aminated resorcin[4]arenes in water and DMSO at 278.15 K to 303.15 K

Author: Hefter, Glenn ; Espitia-Galindo, Nicolas ; Vargas, Edgar F.

Understanding supramol. chem. requires comprehensive knowledge of macrocycle behavior in solutionThis study reports standard molar volumes and compressibilities of the chloride salts of two cationic macrocycles C-methylresorcin[4]arene-tetraminoethylated-hydrochloride (TAE·(HCl)₄) and their C-Et analog (ETAM·(HCl)₄) in aqueous and DMSO solutionsThese quantities were obtained using d. and speed of sound measurements at concentrations (0.005 to 0.08) mol·kg^-1 and temperatures in the range (278.15 to 308.15) K.NMR techniques were used to study the structures of the macrocycles in solution, while the corresponding compounds were characterised using mass spectrometry, thermogravimetry and differential scanning calorimetry.The partial molar quantities derived from the volumetric and sonometric data are discussed, along with relevant literature information, in terms of solute-solvent interactions.Structural modifications of macrocycles influence the standard molar compressibilities through changes in solvent organization around functional groups, intrinsic compressibility, and water mols. in the resorcinarene cavity.The effect of carbon chain length on the volumes and compressibilities of substituted resorcin[4]arenes is shown to depend on their location in the macrocycle, but not on the solvent.The standard molar volume is shown to be influenced by ionic moieties and intramol. hydrogen bonds.

01 Jun 2025·American Journal of Ophthalmology

Unplanned Return to the Operating Room After Cataract Surgery

Article

Author: Ali, Muhammad ; Khan, Malik Muhammad Hamza ; Akhlaq, Anam ; Schein, Oliver D ; Woreta, Fasika A ; Suazo, Mallory K

PURPOSETo determine the rate of unplanned return to the operating room (OR) within 90 days of cataract surgery and to identify the most common preoperative and intraoperative risk factors.DESIGNRetrospective case-control study.SUBJECTS AND CONTROLSPatients aged ≥40 years undergoing cataract surgery at the Wilmer Eye Institute between 2019 and 2022 with at least 90 days of postoperative follow-up were included. Patients with return to the OR for a reason other than a postoperative complication of cataract surgery in the same eye were excluded. For each case, a time-matched control (cataract surgery within 1 month of the case's surgery) was selected using a random number generator.METHODSThe chi-squared test was used for categorical variables, the student's t-test for continuous variables, and the multivariable logistic regression analysis to assess for associated preoperative and intraoperative factors.MAIN OUTCOME MEASURESThe main outcomes included the rate and the most common reasons for unplanned return to the OR as well as the odds ratios of associated preoperative and intraoperative variables.RESULTSAmong 32,480 eyes, 175 eyes (0.54%) had an unplanned return to the OR within 21 ± 21 days of cataract surgery. The most common reason was retained lens fragments in 88 eyes (50%). Patients with an unplanned return to the OR had a worse mean best-corrected visual acuity preoperatively (Snellen equivalent of ∼20/100 for cases vs 20/50 for controls, p-value < .001) and at last follow-up (cases 20/50, controls 20/30, p-value < .001). There were significantly higher odds of an unplanned return to the OR for patients undergoing complex cataract surgery (odds ratio, 1.80; 95% CI, 1.06-3.05) and for patients with prior tamsulosin use (odds ratio, 2.00; 95% CI, 1.09-3.69).CONCLUSIONSPatients undergoing complex cataract surgery and those with prior tamsulosin use had significantly higher odds of unplanned return to the OR. Monitoring rates of unplanned return to the OR at the institutional and national levels by using national clinical registries or a multicenter study is needed to assist in quality monitoring and to improve patient surgical outcomes.

22

News (Medical) associated with Tamsulosin Hydrochloride

02 Apr 2025

·www.prnewswire.com

Hanmi Pharmaceutical's 'Gugutams' to be Launched in Mexico as 'Aditams', Marking the Start of Full-Scale Latin America Expansion

Hanmi Pharm Begins Local Sales of Urological Product 'Aditams' in Mexico with Partner 'Laboratorios Silanes' Launch completed in February, Hanmi Pharm's Third Product to Enter Latin America Aditams, The First Urological Combination Drug for OPG and ED Exported to Mexico SEOUL, South Korea, April 2, 2025 /PRNewswire/ -- Hanmi Pharmaceutical's combination therapy for Obstructive Prostatic Growth (OPG) caused by Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED), Gugutams, is entering the Mexican market under the local brand name "Aditams." Continue Reading Aditams Hanmi Pharmaceutical announced that it has completed the launch of Aditams in Mexico under the export agreement signed in October 2020 with the Mexican pharmaceutical company 'Laboratorios Silanes'. Under the agreement, Hanmi Pharmaceutical plans to export Gugutams to the Mexican market for a period of seven years, starting in February 2025. Gugutams, developed by Hanmi Pharmaceutical, is the world's first urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). It is also noteworthy as the first prescription drug in Korea to apply Poly-Cap technology, which integrates multiple active ingredients into a single capsule. Laboratorios Silanes, a leading pharmaceutical company in Mexico founded in 1943, is committed to providing innovative healthcare solutions and driving rapid growth in the industry. It has established itself as a key player in the Latin American pharmaceutical market through its robust distribution network and strategic collaborations with global partners. Silanes previously collaborated with Hanmi Pharmaceutical in 2023 to successfully introduce the hypertension and dyslipidemia combination treatment 'Amosartan Q', under the local brand 'Lodarta' and in 2024 to introduce the combination hypertension treatment 'Amosartan Plus' under the local brand 'Bicartial-CTD'. Following these products, Gugutams, under the local brand 'Aditams', becomes Hanmi Pharmaceutical's third product in the Latin American region. Aditams, as the first urological combination therapy to enter the Mexican market, is expected to offer a new treatment option for patients suffering from both Obstructive Prostatic Growth (OPG) and erectile dysfunction (ED). By managing both conditions with a single medication, it significantly enhances patient convenience and maximizes therapeutic efficacy. Hanmi continues to focus on expanding its partnerships in emerging markets such as the Middle East and Latin America, in addition to its established presence in developed markets like North America and Japan. The company aims to leverage strategic partners like Laboratorios Silanes as key footholds to broaden its product portfolio and regional reach. Park Jae-hyun, CEO of Hanmi Pharmaceutical, stated, "As the first urological combination therapy to enter the Mexican market, Gugutams is expected to present a new treatment paradigm for local patients." He added, "Through this collaboration with Laboratorios Silanes, we aim to solidify Hanmi Pharmaceutical's presence in the Latin American market and leverage this as a foundation to further strengthen our competitiveness in the global pharmaceutical industry." Official Websites: About Hanmi Pharmaceutical: Hanmi Pharmaceutical is an R&D-focused pharmaceutical company committed to developing globally innovative therapies in areas of high unmet medical needs such as obesity/metabolism, oncology, and rare diseases. Hanmi leverages proprietary platform technologies, including long-acting biologics and bispecific antibodies, to address unmet medical needs. The company emphasizes open innovation and has established numerous global partnerships to advance its research and development efforts. SOURCE Hanmi Pharmaceutical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalLicense out/inBiosimilar

21 Jun 2024

·pmlive.com

Study suggests enlarged prostate drugs could protect against dementia with Lewy bodies

Researchers from the University of Iowa (UI) Health Care have suggested that certain drugs used to treat enlarged prostates have the potential to decrease the risk of dementia with Lewy bodies (DLB). Published in Neurology , the study revealed that three enlarged prostate drugs were able to increase the energy production in brain cells. Affecting one in every 1,000 people per year, DLB is the second most common type of dementia, which occurs when protein deposits called Lewy bodies develop in nerve cells in the brain, affecting thinking, memory and movement. Researchers identified more than 643,000 men with no history of DLB who were newly starting one of six drugs used to treat benign prostatic hyperplasia and followed the participants for around three years from when they started taking the medication until they left the database or developed DLB. The observational study found that the already-approved Abbott’s Hytrin (terazosin), Pfizer’s Cardura (doxazosin) and Sanofi’s Uroxatral (alfuzosin) boosted the energy production in brain cells, which could help to slow or prevent neurodegenerative diseases including DLB and Parkinson’s disease (PD), while the three other drugs, tamsulosin and two 5-alpha-reductase inhibitors (5ARIs), finasteride and dutasteride, did not. Men who took terazosin had around a 40% lower risk of developing DLB versus men taking tamsulosin and about a 37% reduction in risk compared to men taking 5ARIs, with no statistically significant difference in risk between men taking tamsulosin and ARIs. “If terazosin and these similar medications can help slow this progression – if not outright preventing the disease – this would be important to preserving cognitive function and quality of life in people with DLB,” said lead study author, Jacob Simmering, UI assistant professor, internal medicine. Previous studies have already linked certain drugs and treatments to other neurodegenerative conditions. In February, researchers from University College London revealed that erectile dysfunction drugs could also be linked to a reduced risk of developing Alzheimer’s disease (AD), the most common form of dementia. Of nearly 270,000 men over the age of 40, those who were prescribed phosphodiesterase 5 inhibitors were 18% less likely to develop AD compared to those who were not.

Clinical ResultDrug Approval

20 Jun 2024

·www.biospace.com

Prostate Drugs May Find New Use in Reducing Risk of Dementia: Study

Pictured: Concept art showing an elderly woman overlaid with an illustration of a brain/iStock, boonstudio Drugs commonly used for the treatment of enlarged prostate may also help lower the risk of dementia with Lewy bodies, according to a new observational study from the University of Iowa Health Care. Drawing from Merative MarketScan, one of the largest proprietary U.S. healthcare claims databases, University of Iowa researchers identified more than 643,000 men who were starting treatment for benign prostatic hyperplasia with one of six common therapies. Three of these drugs fell under the class of α-1 adrenergic receptor antagonists, better known as α-blockers, which work by inhibiting the contraction of smooth muscles. The researchers focused on terazosin, which is sold by Abbott under the brand name Hytrin, doxazosin, which is marketed by Pfizer as Cardura, and alfuzosin, which is branded as Uroxatral by Sanofi. Alpha-blocker drugs are known to have a unique side effect: they activate a key enzyme involved in the production of ATP, which is the molecular form of cellular energy. In the brain, these drugs can help boost the production of energy and fight neurodegeneration, the University of Iowa scientists hypothesized. As active comparators, the researchers also followed men in Merative MarketScan who were being treated with tamsulosin or with the 5α-reductase inhibitors (5ARI) finasteride and dutasteride, all of which are not known to affect energy production in the brain. The men included in the study had no history of dementia with Lewy bodies (DLB). Participants were then followed until they exited the database or until they developed DLB. After an average follow-up of around three years, the study found that men who were initiated on the three alpha-blocker drugs were 40% less likely to develop DLB than comparators who were on tamsulosin. Compared with men whose enlarged prostates were being treated with 5ARI agents, the risk of DLBA was 27% lower in those taking alpha-blocker drugs. Both effects were statistically significant. By contrast, DLB had a statistically similar likelihood of developing in men being managed with tamsulosin and 5ARIs. These results were robust to several sensitivity analyses, according to researchers. The University of Iowa scientists published their findings Wednesday in Neurology, the medical journal of the American Academy of Neurology. “If terazosin and these similar medications can help slow this progression—if not outright preventing the disease—this would be important to preserving cognitive function and quality of life in people with DLB,” Jacob Simmering, assistant professor of internal medicine at the University of Iowa and lead study author, said in a statement. However, the researchers caution that the study is simply observational in design and only shows that there is a statistical correlation between the use of alpha-blocker drugs and the reduced risk of DLB. It does not establish causation nor does it show any directionality of association, they said. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

Clinical Result

100 Deals associated with Tamsulosin Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01024	Tamsulosin Hydrochloride	G04CA02	DB00706

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Lower Urinary Tract Symptoms	Luxembourg	Astellas Pharma Europe BV	01 Mar 2005
Lower Urinary Tract Symptoms	Belgium	Astellas Pharma Europe BV	01 Mar 2005
Prostatic Hyperplasia	Japan	Astellas Pharma, Inc.	02 Jul 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Urinary Bladder, Neurogenic	Preclinical	Brazil	Boehringer Ingelheim GmbH	01 Jan 2008
Urinary Bladder, Neurogenic	Preclinical	Germany	Boehringer Ingelheim GmbH	01 Jan 2008
Urinary Bladder, Neurogenic	Preclinical	Philippines	Boehringer Ingelheim GmbH	01 Jan 2008
Urinary Bladder, Neurogenic	Preclinical	Russia	Boehringer Ingelheim GmbH	01 Jan 2008
Urinary Bladder, Neurogenic	Preclinical	Belgium	Boehringer Ingelheim GmbH	01 Jan 2008
Lower Urinary Tract Symptoms	Preclinical	Japan	Astellas Pharma, Inc.	17 Oct 2005
Urologic Diseases	Preclinical	Japan	Astellas Pharma, Inc.	17 Oct 2005
Prostatic Hyperplasia	Preclinical	United States	Sanofi-Aventis U.S. LLC	15 Apr 1997

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


P11-3.020 (AAN2025)	Not Applicable	Prostatic Hyperplasia	-	Tamsulosin	pnxqoixtai(ejaopvyrmj): HR = 0.63 (95% CI, 0.53 - 0.76), P-Value = < 0.001 View more	Positive	07 Apr 2025
				5-α reductase inhibitors (5ARI)
NCT03750656 (HyTa Stent, CTgov)	Phase 4	Lower Urinary Tract Symptoms	5	Hyoscyamine (Hyoscyamine)	mdjrfzjruk(ezuapdgrhd) = agacikqikk brtbjnpaes (eakcwxwclw, vsliftpbdb - nselylypyp) View more	-	03 Dec 2024
				Tamsulosin (Tamsulosin)	mdjrfzjruk(ezuapdgrhd) = ckrjlojtif brtbjnpaes (eakcwxwclw, ftwojfoalc - ushtnbpwfd) View more
NCT01568918 (CTgov)	Phase 3	Urinary Retention	90	Tamsulosin hydrochloride (Tamsulosin)	gbohkkpwaj(cjwryuysul) = ijjvojnrtn mjnjuktuog (upscnekuns, usvzegzokq - upwwlngiuy) View more	-	30 May 2024
				Placebo (Placebo)	gbohkkpwaj(cjwryuysul) = hazwwuqtbp mjnjuktuog (upscnekuns, eolwyeiqkg - rledawdypz) View more
MP26-09 (AUA2024)	Not Applicable	-	200	Tamsulosin	rqwygyykei(fqygegfypz) = xnyplrdjrn igbybgfipy (mksrofpvmz )	Positive	01 May 2024
				Placebo	rqwygyykei(fqygegfypz) = itmbtgsehn igbybgfipy (mksrofpvmz )
NCT04859660 (A Randomized Controlled Trial, CTgov)	Phase 2	Urinary Retention	161	Tamsulosin (Tamsulosin- Intervention Group)	mtfduqxduy(wqwhmhbtsb) = bauujwomnl wdgsgkunkg (sfasffbthp, tikyuhusiv - grrmxituqk) View more	-	29 Feb 2024
				Placebo (Placebo Group)	mtfduqxduy(wqwhmhbtsb) = bccumivdze wdgsgkunkg (sfasffbthp, xlckxqoejj - roxpdxgfbz) View more
NCT04682366 (CTgov)	Phase 4	Urinary Retention	4	Tamsulosin (Tamsulosin)	wiqsyeegii(bupgnhtqdg) = oxzwxyiygr wrovkiwtoy (lyshhjqwna, libjxbmyjc - eufckvkasa) View more	-	31 Jan 2024
				Placebo (Placebo)	wiqsyeegii(bupgnhtqdg) = larxdzbcmm wrovkiwtoy (lyshhjqwna, bfxwroxoae - yhnuohkcts) View more
MP24-17 (AUA2023)	Not Applicable	Prostatic Hyperplasia	160	Tamsulosin	ecqwxnspgd(bvdkiewkte) = ybbkkpzqgu jfnxicundd (wfldcwioxd )	-	01 Apr 2023
				Tadalafil 5 mg	ecqwxnspgd(bvdkiewkte) = jasxpxlozq jfnxicundd (wfldcwioxd )
APAO2023	Not Applicable	Intraoperative floppy iris syndrome (IFIS) Tamsulosin	54	Tamsulosin	xamllqcekj(fanhykxgwf) = tijwewspoy sebxuzwdwz (hvwwpeddzs )	Positive	23 Feb 2023
NCT04819828 (Pubmed \| Int J Clin Pract)	Phase 4	Kidney Calculi Adjuvant	60	Tamsulosin	nlevswwuck(iavfolzjsx) = ajzgwfczmm xnufiqknhd (eqemjpamkx )	Negative	01 Jan 2022
				tamsulosin (Control)	nlevswwuck(iavfolzjsx) = dsvqmwfmtx xnufiqknhd (eqemjpamkx )
NCT03524339 (CTgov)	Phase 2/3	Pelvic Organ Prolapse \| Urinary Incontinence, Stress \| Urinary Retention \| Lower Urinary Tract Symptoms	132	Placebo oral capsule (Placebo)	aqlpgztcgf(gslfhajkhm) = tskrxfxlho hnexhduvzq (tmriqnlhvw, vpcaihzydl - citzqoozsl) View more	-	08 Nov 2021
				Tamsulosin (Tamsulosin)	aqlpgztcgf(gslfhajkhm) = ujzmbzchdi hnexhduvzq (tmriqnlhvw, zfijjxizyo - amnqbjjhqa) View more